





Oligosaccharide-based Vaccines

Description



Oligosaccharide-based vaccines against pathogenic bacteria

Poorly immunogenic in persons of high risk groups; thymus-independent type 2 antigens; IgM.







Harm
Immu

A switch to T-cell dependent response



CPS of *S. pneumoniae* serotype 14 (Pn14PS)




Oligosaccharide approach:


From CPS: Hydrolysis mixtures of oligosaccharides with respect to chain length and presented epitopes for conjugation.

From CPS: Isolation of specific fragments followed by hydrolysis mixtures for conjugation.

Our approach: Via chemical synthesis (eventually combined with enzymatic synthesis) of oligosaccharides from monosaccharides.



Synthesis of Pn14OS-protein conjugates using series of synthetic Pn14OS



INFECTION AND IMMUNITY, Oct. 2008, p. 4615–4623
 0019-9567/08/\$08.00+0 doi:10.1128/IAI.00472-08
 Copyright © 2008, American Society for Microbiology. All Rights Reserved.


Vol. 76, No. 10

Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against *Streptococcus pneumoniae* Type 14⁷

Dodi Safari,¹ Huberta A. T. Dekker,¹ John A. F. Joosten,² Dirk Michalik,² Adriana Carvalho de Souza,² Roberto Adamo,² Martina Lahmann,³ Andreas Sundgren,³ Stefan Oscarson,^{3,4} Johannis P. Kamerling,² and Harm Snippe^{1*}

Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands¹; Bijvoet Center, Department of Bio-Organic Chemistry, Utrecht University, Utrecht, The Netherlands²; Department of Organic Chemistry, Stockholm University, Stockholm, Sweden³; and Centre for Synthesis and Chemical Biology, University College Dublin, Dublin, Ireland⁴

Received 16 April 2008/Returned for modification 17 May 2008/Accepted 24 July 2008



Category

1. News